Literature DB >> 18356690

Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.

Mohammad Anwar Hossain1, Maki Tsujita, Frank J Gonzalez, Shinji Yokoyama.   

Abstract

Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through activating peroxisome proliferater activated receptor (PPAR)-alpha. We investigated the effects of fibrates to induce expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1) and increase HDL biogenesis in hepatocytes. Fenofibrate, bezafibrate, gemfibrozil, and LY518674 were tested for HepG2 cells and primary-cultured mouse hepatocytes. All the compounds examined increased ABCA1 expression and HDL biogenesis dependent on PPARalpha in association with the liver X receptor alpha upregulation. While fenofibrate and LY518674 showed exclusive dependency on PPARalpha for these activities, bezafibrate and gemfibrozil exhibited dependency on PPARbeta/delta and PPARgamma as well. On the other hand, cholesterol-enrichment of HDL may involve PPARgamma for fenofibrate and bezafibrate, and PPARbeta/delta for the fibrates examined except for bezafibrate. We concluded that fibrates enhance expression of ABCA1 in hepatocytes to contribute to increase of the HDL biogenesis in a PPAR-dependent manner, whether exclusively or nonexclusively on PPARalpha.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356690     DOI: 10.1097/FJC.0b013e3181624b22

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

1.  Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Naoki Tanaka; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.

Authors:  Michael Y Tsai; Jose M Ordovas; Na Li; Robert J Straka; Naomi Q Hanson; Valerie L Arends; Donna Arnett
Journal:  Mol Genet Metab       Date:  2010-03-06       Impact factor: 4.797

3.  Fibrate pharmacogenomics: expanding past the genome.

Authors:  John S House; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2020-03-17       Impact factor: 2.533

4.  A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial.

Authors:  Michele L Mietus-Snyder; Mark K Shigenaga; Jung H Suh; Swapna V Shenvi; Ashutosh Lal; Tara McHugh; Don Olson; Joshua Lilienstein; Ronald M Krauss; Ginny Gildengoren; Joyce C McCann; Bruce N Ames
Journal:  FASEB J       Date:  2012-05-01       Impact factor: 5.191

5.  Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.

Authors:  Sophie Colin; Olivier Briand; Véronique Touche; Kristiaan Wouters; Morgane Baron; François Pattou; Rémy Hanf; Anne Tailleux; Giulia Chinetti; Bart Staels; Sophie Lestavel
Journal:  Eur Heart J       Date:  2012-07-26       Impact factor: 29.983

6.  PPAR-α, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.

Authors:  Vijay R More; Christopher R Campos; Rebecca A Evans; Keith D Oliver; Gary Ny Chan; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 7.  Gemfibrozil, stretching arms beyond lipid lowering.

Authors:  Avik Roy; Kalipada Pahan
Journal:  Immunopharmacol Immunotoxicol       Date:  2009       Impact factor: 2.730

8.  FGF-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to upregulate the apoE gene in rat astrocytes.

Authors:  Rui Lu; Jinichi Ito; Noriyuki Iwamoto; Tomoko Nishimaki-Mogami; Shinji Yokoyama
Journal:  J Lipid Res       Date:  2009-02-19       Impact factor: 5.922

9.  On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

Authors:  Masaki Ogata; Maki Tsujita; Mohammad Anwar Hossain; Nobukatsu Akita; Frank J Gonzalez; Bart Staels; Shogo Suzuki; Tatsuya Fukutomi; Genjiro Kimura; Shinji Yokoyama
Journal:  Atherosclerosis       Date:  2009-01-19       Impact factor: 5.162

Review 10.  Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.

Authors:  Stella Aslibekyan; Robert J Straka; Marguerite R Irvin; Steven A Claas; Donna K Arnett
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.